Tobacco Dependence Clinical Trial
Official title:
An Evaluator-Blinded, Randomized, Parallel Controlled Study of Nicorette® Freshmint Gum Versus Nicorette® Microtab in Healthy Smokers Motivated to Quit Smoking With Visible Staining of Teeth
Participants will be smokers who want to quit, and have visible nicotine stains on their teeth. They will be given toothpaste and a toothbrush to use during the study, and will have an equal chance of being assigned to use either a nicotine gum or microtab. They will visit the study site five times during the 12 week trial to have their teeth examined.
Status | Completed |
Enrollment | 200 |
Est. completion date | November 2005 |
Est. primary completion date | November 2005 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Males and females aged 18 to 65 years - Daily smoker, current daily smoking for at least 1 year - Motivated to quit smoking, and willing to use NRT (nicotine gum or nicotine sublingual tablet) - Normal chewing abilities (able to use chewing gum without any problems) - Willing to refrain from dental prophylaxis for the duration of the 12-week trial - Have a minimum of 20 natural teeth, with at least 10 of the 12 anterior teeth present and scorable. - Have a total extrinsic facial tooth stain score equal or more than 28, according to the MacPherson Modification of the Lobene Stain Index. - Willing and able to comply with scheduled visits, treatment plan, tests, and other trial procedures. Exclusion Criteria: - Use of other tobacco-containing products, such as cigars, pipe, smokeless tobacco products, etc. - Existing use of any nicotine replacement products for smoking cessation, or undergoing any other treatment for tobacco dependence, such as hypnosis, acupuncture, bupropion, etc. - Orthodontic appliances - Gross periodontal disease, or signs of gross oral neglect - History of oral cancer - History of temporomandibular joint disorders known to aggravate jaw pain - Unstable angina pectoris or myocardial infarction during the previous 3 months - Pregnancy, lactation or intended pregnancy - Any major metabolic disease, clinically important renal or hepatic disease Suspected alcohol or drug abuse - Participation in another clinical trial within the previous three months and during study participation - Any other severe acute or chronic medical or psychiatric condition that might increase the risk associated with trial participation or trial drug administration or may interfere with the interpretation of trial results and, in the judgment of the investigator, makes the subject inappropriate for entry into this trial. |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)
Country | Name | City | State |
---|---|---|---|
Ireland | Dental School and Hospital, University College of Cork | Wilton | Cork |
Lead Sponsor | Collaborator |
---|---|
McNeil AB |
Ireland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from Baseline in Total Extrinsic Tooth Stain Score | Mean change in total extrinsic tooth stain score, for the whole mouth region. Extrinsic tooth staining is measured using the MacPherson Modification of the Lobene Stain Index. A lower stain index score represents a reduction in extrinsic tooth staining. | Baseline, 6 Weeks | No |
Secondary | Change from Baseline in Total Extrinsic Tooth Stain Score | Mean change in total extrinsic tooth stain score, for the whole mouth region, measured using the MacPherson Modification of the Lobene Stain Index. A lower stain index score represents a reduction in extrinsic tooth staining. | Baseline, 2 Weeks | No |
Secondary | Change from Baseline in Total Extrinsic Tooth Stain Score | Mean change in total extrinsic tooth stain score, for the whole mouth region, measured using the MacPherson Modification of the Lobene Stain Index. A lower stain index score represents a reduction in extrinsic tooth staining. | Baseline, 12 Weeks | No |
Secondary | Change from Baseline in Mean Stain Index Facial Region | Mean changes in the extrinsic facial surface stain score between baseline and Weeks 2, 6 and 12. | Baseline through Week 12 | No |
Secondary | Change from Baseline in Mean Stain Index Lingual Region | Mean changes in the extrinsic lingual surface stain score between baseline and 2, 6 and 12 weeks. | Baseline through Week 12 | No |
Secondary | Change from Baseline in Mean Stain Index Body Region | Mean changes in the extrinsic body region stain scores between baseline and 2, 6 and 12 weeks. | Baseline through Week 12 | No |
Secondary | Change from Baseline in Mean Stain Index Gingival Region | Mean changes in the extrinsic gingival region stain scores between baseline and 2, 6 and 12 weeks. | Baseline through Week 12 | No |
Secondary | Change from Baseline in Mean Stain Index Interproximal Region | Mean changes in the extrinsic interproximal region stain scores between baseline and 2, 6 and 12 weeks. | Baseline through Week 12 | No |
Secondary | Change from Baseline in Mean Stain Area Total Region | Mean stain area between baseline and Weeks 2, 6 and 12 for the facial region, lingual region, body region, gingival region, and interproximal region (Total Region). | Baseline through Week 12 | No |
Secondary | Change from Baseline in Mean Stain Area Facial Region | Mean stain area between baseline and Weeks 2, 6 and 12 for the facial region. | Baseline through Week 12 | No |
Secondary | Change from Baseline in Mean Stain Area Lingual Region | Mean stain area between baseline and Weeks 2, 6 and 12 for the lingual region. | Baseline through Week 12 | No |
Secondary | Change from Baseline in Mean Stain Area Body Region | Mean stain area between baseline and Weeks 2, 6 and 12 for the body region. | Baseline through Week 12 | No |
Secondary | Change from Baseline in Mean Stain Area Gingival Region | Mean stain area between baseline and Weeks 2, 6 and 12 for the gingival region. | Baseline through Week 12 | No |
Secondary | Change from Baseline in Mean Stain Area Interproximal Region | Mean stain area between baseline and Weeks 2, 6 and 12 for the interproximal region. | Baseline through Week 12 | No |
Secondary | Change from Baseline in Mean Stain Intensity Total Region | Mean stain intensity between baseline and Weeks 2, 6 and 12 for the facial region, lingual region, body region, gingival region, and interproximal region (Total Region). | Baseline through Week 12 | No |
Secondary | Change from Baseline in Mean Stain Intensity Facial Region | Mean stain intensity between baseline and Weeks 2, 6 and 12 for the facial region. | Baseline through Week 12 | No |
Secondary | Change from Baseline in Mean Stain Intensity Lingual Region | Mean stain intensity between baseline and Weeks 2, 6 and 12 for the lingual region. | Baseline through Week 12 | No |
Secondary | Change from Baseline in Mean Stain Intensity Body Region | Mean stain intensity between baseline and Weeks 2, 6 and 12 for the body region. | Baseline through Week 12 | No |
Secondary | Change from Baseline in Mean Stain Intensity Gingival Region | Mean stain intensity between baseline and Weeks 2, 6 and 12 for the gingival region. | Baseline through Week 12 | No |
Secondary | Change from Baseline in Mean Stain Intensity Interproximal Region | Mean stain intensity between baseline and Weeks 2, 6 and 12 for the interproximal region. | Baseline through Week 12 | No |
Secondary | Change from Baseline in Mean Tooth Shade | Mean tooth shade between baseline and Weeks 2, 6, and 12 using the Vita® Shade Guide. A higher number represents a lighter tooth shade. | Baseline through Week 12 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01928719 -
Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status
|
N/A | |
Completed |
NCT01995123 -
Behavioral Activation for Smoking Cessation in PTSD
|
N/A | |
Not yet recruiting |
NCT03249428 -
E-Cigarette Inner City RCT
|
N/A | |
Recruiting |
NCT02564289 -
Cardiovascular Effects of Chronic Snus Use
|
N/A | |
Completed |
NCT01928758 -
Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders
|
N/A | |
Withdrawn |
NCT01847300 -
cSBI-M for Young Military Personnel
|
N/A | |
Completed |
NCT01570595 -
Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV
|
Phase 1/Phase 2 | |
Completed |
NCT01428310 -
Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke
|
Phase 1 | |
Recruiting |
NCT00977249 -
Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT00968513 -
Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry
|
Phase 3 | |
Completed |
NCT00747643 -
Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement
|
N/A | |
Completed |
NCT00722124 -
S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence
|
Phase 2/Phase 3 | |
Completed |
NCT01113424 -
Bioequivalence Between Nicotine Replacement Products and Nicorette® Gum
|
N/A | |
Completed |
NCT01238627 -
Bioequivalence Between Two Oral Nicotine Sublingual Tablets, 2 mg and 4 mg
|
N/A | |
Completed |
NCT01228617 -
Single-dose Pharmacokinetics of Oral Nicotine Replacement Products
|
N/A | |
Completed |
NCT00296647 -
Smoking Cessation Intervention: Effectiveness in Primary Care
|
Phase 4 | |
Completed |
NCT00394420 -
Emergency Department Telephone Quitline
|
N/A | |
Recruiting |
NCT05487807 -
Adapting and Evaluating a Tobacco Use Cessation Program for People Living With HIV in Uganda and Zambia
|
Phase 1 | |
Completed |
NCT03553992 -
An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers
|
N/A | |
Withdrawn |
NCT05440721 -
Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification
|
N/A |